Major Adverse Cardiovascular Events - Globe Thesis

Keyword [Major Adverse Cardiovascular Events] Result: 41 - 60 \| Page: 3 of 9
41.	Establishment Of CYP2C19 Gene Polymorphism Detection And Its Clinical Applications
42.	Intermediate-term Clinical Outcomes Of Coronary Heart Disease Treated By Everolimus-eluting Stent Or Rapamycin-eluting Stent
43.	Risk Of Major Adverse Cardiovascular Events In Patients With Metabolic Syndrome After Revascularization: A Meta-analysis Of Eighteen Cohorts With 18457 Patients
44.	Macrophage Migration Inhibitory Factor As A Novel Biomarker For The Severity And Prognosis Of Coronary Heart Disease
45.	Clinical Evaluation Of The Relationship Between PCSK9 And The Development Of Coronary Heart Disease
46.	Value Of Modified Shock Index For Predicting Short-Term Outcomes In Patients With ST-Segment Elevation Myocardial Infarction
47.	Effects Of LDL-C Level On The Incidence Of Major Adverse Cardiovascular Events In Patients Undergoing Percutaneous Coronary Intervention
48.	The Value Of CK-MB In Risk Stratification And Prediction Of In-hospital Major Adverse Cardiovascular Events Among Patients With Nonst-segment-elevation Myocardial Infarction
49.	The Relationship Between Epicardial Adipose Tissue And Clinical Prognosis Of Coronary Heart Disease For Patients With Percutaneous Coronary Intervention
50.	The Predictive Value Of Glycated Hemoglobin For Adverse Cardiovascular Events In Patients With Acute Myocardial Infarction
51.	The Relationship Between Plasma Level Of MicroRNA-1 And Coronary Heart Disease Diagnosis Or Prognosis
52.	The Efficacy And Safety Of Paclitaxel-coated Balloon In The Treatment Of Drug-eluting Stent In-stent Restenosis
53.	Efficacy And Safety Of Reoperative Loading Of Ticagrelor On Emergency Interventional Therapy In STEMI Patients
54.	Efficacy Of Drug Therapy In Patients With Acute Myocardial Infarction And Analysis Of The Reasons For Drug Therapy
55.	The Study Of Correlation Between Left Atrial Volume Index And Major Adverse Cardiovascular Events After Acute Coronary Syndrome
56.	The Current Status Of Secondary Prevention After Percutaneous Coronary Intervention In Patients With Acute Coronary Syndrome
57.	The Correlation Between Soluble ST2 And Myocardial Fibrosis And Major Cardiac Adverse Events After Acute Myocardial Infarction
58.	Clinical Analysis Of Different CYP2C19 Genotypes In Patients With Acute Coronary Syndrome
59.	Prediction Of Long-term Prognosis Based On Neutrophil-lymphocyte Ratio In Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention
60.	Predictive Value Of Platelet-to-lymphocyte Ratio Combined With GRACE Score For The Prognosis In Patients With Acute Coronary Syndrome
<<First <Prev Next> Last>> Jump to